Other

Duramed Pharmaceuticals, Inc.

Endeavor Pharmaceuticals

Barr Laboratories, Inc.

Robert R Whittle

Grayson Walker Stowell

Frederick D Sancilio

Douglas John Jenkins

Linda B Whittall

Edward N Hill

Glenn A Meyer

Steven A Fontana

Thomas W Leonard

Katherin M Schlipp

Linda D Whittall

Dean G Shirazi

Gerald Sakowski

Novel estrogenic compounds of Formula I are provided. wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, Ris selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, Rdoes not exist; Ris lower alkyl; Rmay be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and Rthrough Rmay independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower alkyl, lower alkoxy, halogen, and carbonyl groups and Ris selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When Ris hydroxy, the hydroxy or ester substituent may have either an &#x3b1; or a &#x3b2; orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.

Estrogenic compounds, pharmaceutical compositions and formulations comprising the same

Estrogenic compounds and pharmaceutical formulations comprising the same

Estrogenic compounds, methods of using and methods of administering the same

Estrogenic compounds and topical pharmaceutical formulations of the same

Novel estrogenic compounds of Formula I are provided. wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, Ris selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, Rdoes not exist; Ris lower alkyl; Rmay be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and Rthrough Rmay independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower allyl, lower alkoxy, halogen, and carbonyl groups and Ris selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When Ris hydroxy, the hydroxy or ester substituent may have either an &#x3b1; or a &#x3b2; orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.

(3) and (6) substituted estrogenic compounds

The present invention relates to novel estrogenic compounds. The present invention also relates to methods of treating estrogen deprivation in a subject comprising administering novel estrogenic compounds. Additionally, the present invention relates to methods of synthesizing novel estrogenic compounds.

C(14) estrogenic compounds

A composition of matter is provided having a mixture of active estrogenic compounds. The mixture is present in chemically pure form. The mixture includes salts of conjugated estrone, conjugated equilin, conjugated &#x394;-dehydroestrone, conjugated 17&#x3b1;-estradiol, conjugated 17&#x3b1;-dihydroequilin, conjugated 17&#x3b2;-dihydroequilin, conjugated 17&#x3b2;-estradiol, conjugated equilenin, conjugated 17&#x3b1;-dihydroequilenin, and conjugated 17&#x3b2;-dihydroequilenin. The mixture also contains the same essential estrogenic compounds present in naturally derived equine conjugated estrogens. Drug products including the composition of matter are also provided, as are methods of using these drug products to treat mammals in need of treatment. Methods of analyzing mixtures containing conjugated estrogens are also provided.

Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds

Novel estrogenic compounds of Formula I are provided.wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, Ris selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, Rdoes not exist; Ris lower alkyl; Rmay be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and Rthrough Rmay independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower alkyl, lower alkoxy, halogen, and carbonyl groups and Ris selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When Ris hydroxy, the hydroxy or ester substituent may have either an &#x3b1; or a &#x3b2; orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.

(3) and (6) substitued estrogenic compounds

Fourier Transform Raman Spectroscopy (FT-Raman) determines the isomer ratio of chemical compositions.

FT-Raman spectroscopic measurement

Compounds represented by formula (Ia) are disclosed by the invention, along with compositions and complexes thereof, optionally in combination with compounds of formula (Ib). Pharmaceutical formulations and methods of making and using such compounds are also disclosed.

Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same

The present invention provides processes for purifying 6-methoxy omeprazole, products using such processes, pharmaceutical formulations using such products, and methods of using such products for gastric acid inhibition.

Growing community of inventors

Wilmington, NC, United States of America

Robert R Whittle